EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2026 Update: Treatment of Relapsing and Metastatic
Take-home: The 2026 EAU-EANM-ESTRO-ESUR-ISUP-SIOG prostate cancer guidelines incorporate evidence published from 2023–2025 and strengthen recommendations across relapsing, metastatic hormone-sensitive, and castration-resistant disease. Risk stratification can inform salvage treatment, while therapeutic options continue to expand through AR pathway inhibitors, metastasis-directed therapy, PARP inhibitors, combinations, and PSMA-based treatments. The update highlights increasingly multidisciplinary management, while acknowledging that recommendations may vary with healthcare-system resources, reimbursement, and treatment access
About this highlight
Read the source: European Urology
- Type
- Regulatory news
- Topic
- Genitourinary
